Comprehensive Cardiovascular Nursing: CAD, ACS, Heart Failure, and Aortic Aneurysms

Coronary Artery Disease: Pathophysiology and Progression

  • Coronary artery disease (CAD) is a blood vessel disorder classified under atherosclerosis, defined by the progressive buildup of soft fatty deposits (atheromas) that harden with age within the arterial wall.

  • Clinical significance and epidemiology:

    • CAD is the most common cardiovascular disorder and the leading cause of death in the United States.

    • It can affect any artery in the body, but when it develops within the coronary arteries, it directly compromises blood supply to the myocardium and can lead to myocardial infarction (MI).

    • Disease progression may remain clinically silent and asymptomatic for decades before manifesting as chronic stable angina or acute coronary syndrome (ACS).

  • Pathophysiological stages of atherosclerosis:

    • Chronic endothelial injury:

    • Initiated by endothelial damage from multiple circulating and mechanical insults, including hypertension, tobacco use, hyperlipidemia (specifically elevated low-density lipoprotein [LDL]), hyperhomocysteinemia, diabetes mellitus, systemic infections, and local/circulating toxins.

    • Endothelial disruption increases permeability, promotes vascular inflammation, and allows circulating lipids to penetrate the arterial intima.

    • Fatty streak:

    • Represents the earliest identifiable macroscopic lesion of atherosclerosis.

    • Characterized by lipids that accumulate and migrate into vascular smooth muscle cells and macrophages (foam cells).

    • Macroscopically appears yellow in color.

    • Clinically observable in coronary arteries by age 2020.

    • Treatment focuses on aggressive reduction of circulating LDL cholesterol; reversal or stabilization of the fatty streak is a slow, gradual process.

    • Fibrous plaque:

    • Progression occurs when collagen covers the fatty streak, forming a firm, raised fibrous cap.

    • Macroscopically appears grey or white in color.

    • Clinically identifiable by age 3030.

    • The expanding plaque progressively narrows the vessel lumen, significantly reducing coronary blood flow.

    • Fissures, surface ulcerations, and cracks can develop across the plaque.

    • Complicated lesion (critical danger):

    • Characterized by plaque rupture, surface ulceration, or fissure enlargement that exposes the thrombogenic lipid core to the bloodstream.

    • Triggers immediate platelet aggregation and thrombus formation over the ruptured cap.

    • Results in rapid, severe luminal narrowing or total thrombotic occlusion of the coronary vessel.

    • Decreased blood flow causes critical deficits in myocardial oxygen (O2O_2) perfusion, precipitating acute ischemia or infarction.

Four stages of atherosclerosis progression from chronic endothelial injury to complicated lesion
  • Collateral circulation:

    • Arterial anastomoses or microvascular bypass channels that develop around a partially or slowly occluded coronary artery.

    • When an atherosclerotic lesion obstructs arterial blood flow over an extended duration, the body responds by opening and enlarging collateral vessels to reroute blood flow around the blockage and sustain downstream perfusion.

Development of collateral circulation bypassing an arterial stenosis

Chronic Stable Angina: Presentation and Clinical Management

  • The CAD clinical continuum:

    • Atherosclerotic CAD branches clinically into chronic stable angina or acute coronary syndrome (ACS).

    • Chronic stable angina can destabilize when a plaque ruptures, evolving into acute coronary syndrome (unstable angina, NSTEMI, or STEMI).

Clinical continuum and branching pathways of coronary artery disease
  • Clinical features of chronic stable angina:

    • Chest discomfort or pain that occurs intermittently over a prolonged period with the same pattern of onset, duration, and intensity of symptoms.

    • Highly predictable; episodes typically last between 5–15 minutes5\text{--}15\,\text{minutes}.

    • Precipitated by situations that increase myocardial oxygen demand, such as physical exertion, emotional stress, heavy meals, or temperature extremes.

    • Symptoms are predictably relieved by rest or the administration of sublingual nitroglycerin (NTG).

  • Sublingual nitroglycerin dosing protocol:

    • At the onset of chest discomfort, the patient must immediately cease physical activity and place 1 nitroglycerin tablet under the tongue.

    • Wait 5 minutes5\text{ minutes}.

    • If chest pain persists or is only partially relieved, take a second sublingual dose and wait an additional 5 minutes5\text{ minutes}.

    • Up to a maximum of 3 doses may be taken, spaced 5 minutes5\text{ minutes} apart (over a total of 15 minutes15\text{ minutes}).

    • If chest discomfort is not relieved after taking 3 nitroglycerin tablets, an evolving myocardial infarction must be assumed, and emergency medical services (call 911) must be activated immediately.

  • Critical pharmacology warnings and contraindications:

    • Nitrates are strictly contraindicated in patients taking phosphodiesterase-5 (PDE-5) inhibitors, such as sildenafil (Viagra), within the preceding 24–48 hours24\text{--}48\text{ hours}, due to the risk of severe, fatal refractory hypotension.

    • New-onset chest pain or pain occurring at rest is not chronic stable angina and requires immediate emergency evaluation.

Acute Coronary Syndrome: Mechanisms, Presentation, and Triage

  • Core pathophysiological definitions:

    • Ischemia: Insufficient blood supply and oxygen deprivation to myocardial tissue; condition is cellularly reversible if blood flow is promptly restored.

    • Infarction: Irreversible tissue necrosis and cell death caused by severe, persistent hypoperfusion.

  • Etiology and cellular timeline of ACS:

    • Plaque destabilization: Plaque deterioration leads to fibrous cap rupture, subendothelial exposure, platelet activation, and localized thrombus formation.

    • Partial coronary artery occlusion causes unstable angina (UA) or non-ST-segment-elevation myocardial infarction (NSTEMI).

    • Total coronary artery occlusion causes ST-segment-elevation myocardial infarction (STEMI).

    • Cellular hypoxia timeline under total occlusion:

    • Myocardial cells become hypoxic within 10 seconds10\text{ seconds} of flow cessation.

    • Cells switch from aerobic to anaerobic metabolism, generating elevated levels of lactic acid.

    • Myocytes remain viable for approximately 20 minutes20\text{ minutes}; beyond this threshold, myocardial injury becomes irreversible and necrosis develops unless collateral flow exists.

    • If reperfusion occurs within 20 minutes20\text{ minutes}, aerobic metabolism is reestablished, contractile function returns, and cellular repair proceeds.

  • Classifications across the ACS spectrum:

    • Unstable Angina (UA):

    • Angina that is new in onset, occurs at rest, or follows an accelerating pattern with increasing frequency, duration, or lower provocation thresholds.

    • Highly unpredictable and constitutes a medical emergency.

    • Electrocardiogram (ECG) reveals normal tracings or non-specific ST-segment depression / T-wave inversion.

    • Serum cardiac biomarkers (cardiac troponins) remain negative.

    • Non-ST-Segment-Elevation Myocardial Infarction (NSTEMI):

    • Partial occlusion causing subendocardial myocardial infarction.

    • ECG demonstrates ST-segment depression or T-wave inversion without ST-segment elevation.

    • Serum cardiac biomarkers (cardiac troponins) are positive / elevated.

    • ST-Segment-Elevation Myocardial Infarction (STEMI):

    • Complete, total occlusion of a major coronary artery causing transmural myocardial infarction.

    • ECG demonstrates progressive ST-segment elevation across leads corresponding to the territory of the occluded artery.

    • Serum cardiac biomarkers (cardiac troponins) are markedly elevated.

    • Requires immediate, emergent reperfusion intervention.

  • Coronary vascular topography and infarction distribution:

    • Right Coronary Artery (RCA): Supplies the right atrium, right ventricle, inferior wall of the left ventricle, and the cardiac conduction system (sinoatrial [SA] and atrioventricular [AV] nodes).

    • Left Anterior Descending (LAD) Coronary Artery: Supplies the anterior wall of the left ventricle and the interventricular septum; extensive proximal LAD occlusions carry high mortality and are clinically referred to as "widow maker" infarctions.

    • Circumflex Coronary Artery: Supplies the lateral and posterior walls of the left ventricle.

Coronary artery anatomy demonstrating acute blockage of the left anterior descending artery

Myocardial Infarction: Pathology, Healing Phases, and Complications

  • Histological and mechanical healing phases:

    • First 24 hours24\text{ hours}:

    • Acute inflammatory reaction begins; leukocyte infiltration (neutrophils and macrophages) occurs within the necrotic zone.

    • Proteolytic enzymes released by neutrophils and macrophages break down and clear necrotic myocardial tissue.

    • 10–14 days10\text{--}14\text{ days} post-MI:

    • Newly developing scar tissue remains thin, weak, and friable.

    • The myocardium is maximally vulnerable to physical stress, structural tearing, or re-injury.

    • Patient activity levels must be carefully restricted and monitored.

    • 6 weeks6\text{ weeks} post-MI:

    • Necrotic muscle is fully replaced by collagenous scar tissue.

    • The infarcted region is considered structurally healed, but it remains permanently non-contractile and less compliant than viable myocardium.

    • Ventricular remodeling:

    • Surviving non-infarcted myocardium dilates and hypertrophies in an attempt to compensate for the lost functional muscle.

    • Remodeling alters ventricular architecture and can precipitate late-stage heart failure.

  • Major clinical complications of acute MI:

    • Dysrhythmias:

    • The most common complication of MI, occurring in 80%–90%80\%\text{--}90\% of all patients.

    • Ventricular tachycardia (VT) and ventricular fibrillation (VF) are the leading causes of sudden cardiac death in the pre-hospital phase.

    • Heart failure:

    • Occurs when the heart's pumping efficiency is impaired, characterized by pulmonary crackles, dyspnea, tachycardia, jugular venous distention, and pulmonary congestion.

    • Cardiogenic shock:

    • Severe left ventricular failure resulting in inadequate tissue perfusion and systemic oxygen delivery.

    • High in-hospital mortality rate; requires immediate inotropic and mechanical circulatory support.

    • Papillary muscle dysfunction or rupture:

    • Infarction of the papillary muscles results in acute mitral valve regurgitation.

    • Manifests as a new systolic murmur and rapid deterioration into acute pulmonary edema and cardiogenic shock.

    • Ventricular aneurysm and pseudoaneurysm:

    • Occurs when the weakened, infarcted ventricular wall bulges outward during systole.

    • Associated with chronic heart failure, persistent dysrhythmias, and mural thrombus formation.

    • Acute pericarditis:

    • Inflammation of the pericardium developing 2–3 days2\text{--}3\text{ days} post-MI.

    • Manifests as sharp, pleuritic chest pain that worsens on deep inspiration, coughing, or movement, and improves when sitting forward; auscultation reveals a friction rub.

    • Dressler syndrome:

    • Secondary autoimmune pericarditis and pleurisy presenting 1–8 weeks1\text{--}8\text{ weeks} after an MI.

    • Clinical features: Pleuritic chest pain, fever, malaise, pericardial friction rub, arthralgia, elevated white blood cell (WBC) count, and increased erythrocyte sedimentation rate (ESR).

    • Treatment of choice: High-dose aspirin.

Diagnostic Biomarkers and Reperfusion Strategies for ACS

  • Serum cardiac biomarker release profiles:

    • Cardiac Troponin (Troponin I and Troponin T):

    • Biomarkers of choice for myocardial necrosis due to exceptional cardiac specificity and sensitivity.

    • Levels begin to rise at 4–6 hours4\text{--}6\text{ hours} after symptom onset.

    • Peak concentration occurs at approximately 15–24 hours15\text{--}24\text{ hours}, reaching multiples up to 50×50\times above normal limits.

    • Remains detectable in serum for 10–14 days10\text{--}14\text{ days}.

    • Creatine Kinase-MB (CK-MB):

    • Myocardial isoenzyme that rises 4–6 hours4\text{--}6\text{ hours} following injury.

    • Peaks between 15–24 hours15\text{--}24\text{ hours} (approximately 15×15\times above normal limits).

    • Returns to normal baseline within 24–36 hours24\text{--}36\text{ hours}; useful for assessing early reinfarction.

    • Myoglobin:

    • Early non-specific oxygen-binding heme protein that rises rapidly within 2–3 hours2\text{--}3\text{ hours}.

    • Peaks early between 3–5 hours3\text{--}5\text{ hours} (reaching nearly 10×10\times baseline).

    • Clears rapidly from the bloodstream, returning to normal within 12–24 hours12\text{--}24\text{ hours}.

Release kinetics of troponin, CK-MB, and myoglobin following acute myocardial infarction
  • Clinical and laboratory diagnostic assessment:

    • Obtain and interpret a 12-lead ECG within 10 minutes10\text{ minutes} of emergency department arrival.

    • Continuous ECG telemetry monitoring.

    • Chest X-ray to evaluate cardiomegaly and pulmonary congestion.

    • Diagnostic laboratory studies: Serial cardiac troponins, CK-MB, myoglobin, complete blood count (CBC), lipid panel, basic metabolic panel (BMP), C-reactive protein (CRP), and serum homocysteine.

    • Diagnostic imaging: Coronary computed tomography angiography (CCTA), echocardiogram, electron beam CT scan, positron emission tomography (PET), exercise or pharmacologic stress testing, and coronary angiography.

  • Emergent reperfusion therapy for STEMI:

    • Emergent Percutaneous Coronary Intervention (PCI):

    • First-line definitive treatment for confirmed STEMI.

    • Door-to-balloon goal: Open the occluded coronary artery within 90 minutes90\text{ minutes} of patient arrival at a facility equipped with a cardiac catheterization laboratory.

    • Employs balloon angioplasty followed by placement of bare-metal stents (BMS) or drug-eluting stents (DES).

    • For severe left ventricular shock or hemodynamic collapse: Hemodynamic stabilization using an intra-aortic balloon pump (IABP) and/or inotropes.

    • Thrombolytic (fibrinolytic) therapy:

    • Indicated when emergent PCI cannot be performed or transport to a PCI-capable facility exceeds established thresholds.

    • Door-to-needle goal: Administer thrombolytic therapy within 30 minutes30\text{ minutes} of arrival.

    • Coronary Artery Bypass Graft (CABG) surgery:

    • Emergent or urgent surgical revascularization indicated for failed PCI, complex multivessel disease, or critical left main coronary artery disease.

Algorithm for the diagnostic assessment and interprofessional medical management of CAD, angina, and ACS
  • Comprehensive drug therapy protocols across ACS:

    • Suspected ACS initial care:

    • 12-lead ECG and continuous rhythm telemetry.

    • Secure immediate intravenous (IV) access.

    • Supplemental O2O_2 therapy for hypoxemic patients.

    • Sublingual or IV nitroglycerin.

    • Chewable Aspirin (162–325 mg162\text{--}325\,\text{mg}).

    • Morphine sulfate for persistent ischemic pain unrelieved by nitroglycerin.

    • Beta-blockers, ACE inhibitors or ARBs, and high-dose statin therapy (e.g., atorvastatin).

    • Unstable Angina / NSTEMI acute medical management:

    • Acute intensive antiplatelet therapy: Aspirin combined with a P2Y12P2Y_{12} receptor inhibitor (clopidogrel [Plavix]) and IV glycoprotein IIb/IIIa inhibitors.

    • Anticoagulation therapy: Unfractionated heparin, low-molecular-weight heparin, or direct thrombin inhibitors.

    • IV nitroglycerin.

    • Diagnostic coronary angiography with intent to perform PCI or CABG.

    • STEMI concurrent medical therapy:

    • Dual antiplatelet therapy (DAPT): Aspirin plus clopidogrel.

    • Systemic anticoagulation (heparin).

    • Beta-blockers, ACE inhibitors, and statins.

  • Nutritional therapy in ACS:

    • Initially placed NPO (except sips of water) until stable and free of acute pain.

    • Diet progresses to a low-sodium, low-saturated fat, and low-cholesterol nutritional plan.

Heart Failure: Etiology, Hemodynamics, and Classifications

  • Overview and systemic impact:

    • Heart failure (HF) is a clinical syndrome characterized by the inability of the heart to pump sufficient blood to meet the metabolic and oxygen demands of peripheral tissues and organs.

    • Precipitated by myocardial insults: Hypertension (HTN), CAD, and acute MI are the primary etiologies.

    • Additional triggers: Congenital heart anomalies (e.g., septal defects), myocarditis/inflammation, chronic dysrhythmias, cardiotoxins (alcohol, illicit drugs, chemotherapy), and comorbid medical conditions.

    • Reduced cardiac output (CO) causes tissue hypoperfusion, impaired alveolar gas exchange, fluid volume overload, and progressive loss of functional capacity.

    • Represents the single most common reason for inpatient hospital admission in adults over the age of 6565.

  • Hemodynamic determinants of cardiac output:

    • Cardiac output equation:

CO=SV×HRCO = SV \times HR

  • Normal resting CO=4–8 L/minCO = 4\text{--}8\,\text{L/min}.

  • Factors regulating Stroke Volume (SV), the quantity of blood ejected with each ventricular contraction:

    • Preload: Volume of blood stretching the ventricles at the end of diastole.

    • Afterload: Systemic vascular resistance against which the left ventricle must exert pressure to eject blood.

    • Myocardial contractility: Inherent force generated by contracting ventricular myocytes.

    • Heart rate (HR): Ventricular beats per minute.

    • Ejection fraction and left-sided heart failure phenotypes:

  • Ejection Fraction (EF) represents the percentage of total left ventricular end-diastolic volume ejected with each systolic stroke.

  • Normal left ventricular ejection fraction (LVEF) is 55%–65%55\%\text{--}65\%.

  • Left-sided heart failure is the most common form of heart failure and encompasses two presentations:

    • Heart Failure with Reduced Ejection Fraction (HFrEF / Systolic HF):

      • Defect in left ventricular contraction and systolic ejection ("lazy left ventricle").

      • Characterized by an LVEF generally <40%<40\%.

      • The left ventricle fails to generate sufficient pressure to eject blood forward through the aorta.

      • Blood backs up retrograde into the left atrium, increasing pulmonary venous and capillary hydrostatic pressures, causing pulmonary congestion and alveolar edema.

      • Causes: Post-MI myocardial injury, chronic elevated afterload (hypertension), dilated cardiomyopathy, and mechanical valve dysfunction.

    • Heart Failure with Preserved Ejection Fraction (HFpEF / Diastolic HF):

      • Defect in left ventricular relaxation and diastolic filling ("stiff left ventricle").

      • Left ventricle becomes stiff, thickened, and non-compliant.

      • Characterized by normal LVEF (55%–65%55\%\text{--}65\%") in the presence of signs and symptoms of HF.

      • Ventricles cannot relax to accommodate normal filling volumes, decreasing forward stroke volume and causing retrograde congestion.

      • Diagnosis confirmed by HF signs/symptoms, normal LVEF, and objective evidence of diastolic dysfunction on echocardiogram or cardiac catheterization.

    • Right-sided heart failure:

  • The right ventricle fails to pump blood forward effectively into the pulmonary arterial bed.

  • Blood backs up retrograde into systemic venous circulation.

  • Manifestations: Dependent peripheral edema, abdominal ascites, hepatomegaly, jugular venous distention (JVD), and rapid weight gain from fluid retention.

  • Etiologies: The primary cause is left-sided heart failure (pulmonary hypertension transmitting resistance backward into the RV); other causes include isolated right ventricular infarction, pulmonary embolism (PE), and cor pulmonale.

    • Compensatory neurohormonal responses and ventricular adaptations:

  • Neurohormonal activation:

    • Renin-Angiotensin-Aldosterone System (RAAS): Promotes renal sodium and water retention, increasing circulating preload and systemic vasoconstriction.

    • Sympathetic Nervous System (SNS): Increases heart rate and peripheral vasoconstriction.

    • Natriuretic peptides (ANP and BNP): Released in response to atrial and ventricular chamber stretch.

  • Ventricular structural adaptations:

    • Dilation: Chamber enlargement accommodating elevated filling pressures.

    • Hypertrophy: Progressive increase in muscle mass and ventricular wall thickness.

    • Remodeling: Chronic structural changes in ventricular architecture, leading to increased wall stress and worsening mechanical function.

    • Chronic complications of heart failure:

  • Pleural effusion: Transudation of fluid into the pleural space causing dyspnea, cough, and chest discomfort.

  • Dysrhythmias and dyssynchronous contraction: Atrial and ventricular dysrhythmias secondary to chamber dilation and altered electrical conduction.

  • Hepatomegaly: Venous engorgement of the liver leading to impaired hepatic function.

  • Cardiorenal syndrome: Severe impairment of renal function caused by decreased cardiac output and inadequate renal perfusion.

  • Anemia.

Acute Decompensated Heart Failure vs. Chronic Heart Failure Management

  • Clinical presentation of Acute Decompensated Heart Failure (ADHF):

    • Sudden acceleration of heart failure symptoms with acute functional decline, frequently requiring emergency department care or intensive care unit (ICU) admission.

    • Dominated by signs of pulmonary congestion and severe volume overload:

    • Interstitial edema: Tachypnea, dyspnea on exertion, shortness of breath.

    • Alveolar edema: Transudation of fluid directly into alveoli, causing hypoxemia, altered arterial blood gases (ABGs), and bilateral crackles.

    • Acute pulmonary edema: Life-threatening emergency characterized by extreme anxiety, pallor, cold/clammy skin, dyspnea, orthopnea, tachypnea (RR>30 breaths/minRR > 30\,\text{breaths/min}"), and persistent coughing.

    • Cardiovascular findings: Sinus tachycardia, presence of S3S_3 or S4S_4 heart sounds.

    • Low perfusion / hemodynamic collapse:

    • Severe decompensation can manifest as hypotension (systolic blood pressure SBP<90 mmHg\text{SBP} < 90\,\text{mmHg} indicates instability), cool and pale extremities, peripheral mottling, oliguria (decreased urine output), cardiac murmurs, and worsening liver and renal function test results.

Clinical signs of acute decompensated heart failure including fluid accumulation, pulmonary edema, and peripheral edema
  • Diagnostic evaluation in heart failure:

    • History and physical examination.

    • 12-lead ECG and Holter monitoring.

    • Chest X-ray to identify cardiomegaly and vascular congestion.

    • Echocardiogram: Primary non-invasive test used to differentiate HFrEF from HFpEF by measuring LVEF and assessing chamber dimensions.

    • Cardiac MRI and cardiac catheterization.

    • 6-minute walk test to evaluate functional capacity and oxygenation status on exertion.

    • B-Type Natriuretic Peptide (BNP):

    • Cardiac hormone synthesized and released by ventricular myocytes in response to increased intracardiac wall tension and volume overload.

    • Normal concentration: <100 pg/mL<100\,\text{pg/mL}.

    • Diagnostic cutoff: Values >100 pg/mL>100\,\text{pg/mL} indicate heart failure, with higher concentrations correlating with severe decompensation.

  • Nursing interventions for ADHF:

    • Continuous vital sign monitoring (SBP<90 mmHg\text{SBP} < 90\,\text{mmHg} signals hemodynamic instability).

    • Pulse oximetry monitoring with supplemental oxygen titration.

    • Continuous telemetry for dysrhythmia detection.

    • Strict daily body weights to track fluid shifts.

    • Frequent neurological checks to evaluate cerebral perfusion.

    • Implementation of sodium restriction and fluid restriction protocols.

    • Therapeutic bed positioning:

    • Place the patient in High Fowler's position with legs horizontal or dangling off the side of the bed.

High Fowler bed positioning to optimize diaphragm mechanics and reduce venous return in heart failure
* Depresses the diaphragm and relaxes abdominal respiratory accessory muscles, improving lung expansion.
* Facilitates venous blood pooling in the dependent extremities, reducing systemic venous return (preload) to an overloaded heart.
  • Drug therapy for ADHF:

    • Diuretics:

    • Loop diuretics (furosemide) and aldosterone antagonists (spironolactone) enhance renal sodium and water clearance to lower circulating volume and preload.

    • Requires close monitoring of serum potassium and magnesium levels.

    • Vasodilators:

    • IV nitroglycerin decreases preload and afterload by dilating venous capacitance and arterial resistance vessels.

    • Restricted to ICU environments; verify blood pressure before initiation and avoid use in hypotensive patients.

    • Morphine sulfate:

    • Dilates arterial and venous vascular beds, reducing preload and afterload.

    • Alleviates dyspnea and associated anxiety; requires monitoring for respiratory depression.

    • Positive inotropes:

    • Increase myocardial contractility for short-term acute hemodynamic stabilization.

    • Efficacy is evaluated by assessing improvements in cardiac index, blood pressure, urine output, and symptom relief.

    • Mandates continuous ECG monitoring due to high dysrhythmic potential.

  • Comprehensive management of chronic heart failure:

    • Nursing and collaborative interventions:

    • Dietary sodium restriction.

    • Fluid volume restriction.

    • Supplemental oxygen as needed.

    • Continuous pulse oximetry.

    • Daily weights: Instruct patients to weigh themselves each morning under consistent conditions and report acute weight gains.

    • Cardiac rehabilitation programs.

    • Pharmacotherapy:

    • ACE Inhibitors: Decrease afterload and reduce blood pressure; potential side effects include a dry persistent cough, hyperkalemia, and peripheral/angioedema; monitor serum potassium and renal function.

    • Angiotensin Receptor Blockers (ARBs): Alternative for patients intolerant of ACE inhibitors; reduce afterload through vasodilation; monitor renal parameters and potassium.

    • Diuretics: Reduce preload, pulmonary congestion, and peripheral edema; monitor for hyponatremia and hypokalemia; rapid intravenous administration of loop diuretics can cause ototoxicity.

    • Aldosterone Antagonists (Spironolactone): Potassium-sparing diuretics that mitigate aldosterone-mediated myocardial fibrosis; monitor for hyperkalemia.

    • Beta-blockers: Inhibit sympathetic activation, decrease heart rate, and improve long-term left ventricular ejection fraction; titrate slowly to the highest tolerated dose; watch for bradycardia and hypotension.

    • Digitalis (Digoxin): Enhances inotropic contractility and reduces HF symptoms; narrow therapeutic range; toxicity signs include visual disturbances (yellow-green halos), nausea, vomiting, and dysrhythmias.

  • Interventions for end-stage heart failure:

    • Continuous outpatient inotropic infusions administered via a peripherally inserted central catheter (PICC) line (e.g., milrinone).

    • Mechanical Circulatory Support (MCS): Implantation of a Left Ventricular Assist Device (LVAD) to mechanically augment or replace the pumping function of the left ventricle.

Left Ventricular Assist Device components providing mechanical circulatory support
  • Orthotopic heart transplantation.

  • Palliative care consultation and hospice enrollment.

Aortic Aneurysm: Types, Clinical Manifestations, and Complications

  • Definition and pathological basis:

    • An aortic aneurysm is a permanent, localized dilation or outpouching of an arterial vessel wall.

    • Aneurysm diameter directly correlates with rupture danger: The larger the aneurysm, the greater the risk for rupture.

  • Etiological classifications:

    • Degenerative processes (atherosclerosis).

    • Congenital connective tissue defects.

    • Mechanical trauma (penetrating or blunt chest/abdominal injuries).

    • Infectious aortitis.

    • Inflammatory conditions (systemic aortitis).

  • Risk factor profiling:

    • Modifiable risk factors: Hypertension (HTN), coronary artery disease (CAD), tobacco use, peripheral artery disease (PAD), hyperlipidemia, and obesity.

    • Non-modifiable risk factors: Advanced age, male sex, and family history / genetic predisposition.

  • Structural classifications of aneurysms:

    • True aneurysm:

    • The arterial wall forms the aneurysm, with at least one vessel wall layer remaining intact.

    • Fusiform aneurysm: Circumferential, uniform, spindle-shaped dilation around the entire circumference of the aortic segment.

    • Saccular aneurysm: Outpouching with a narrow neck projecting from one side of the arterial wall.

    • False aneurysm (pseudoaneurysm):

    • Disruption of all three layers of the arterial wall.

    • Characterized by torn intima/media with bleeding contained by surrounding anatomical structures, adventitia, or a thrombus.

Classifications of true aneurysms, false aneurysms, and ruptured aortic regions
  • Clinical manifestations by anatomical location:

    • Thoracic Aortic Aneurysm (TAA):

    • Frequently asymptomatic upon initial presentation.

    • Deep, diffuse chest discomfort that may radiate into the interscapular back area.

    • Anginal chest pain from coronary compromise.

    • Transient ischemic attacks (TIAs) from microemboli entering carotid vessels.

    • Compression of adjacent structures: Cough, shortness of air (SOA), hoarseness (recurrent laryngeal nerve compression), and dysphagia (esophageal compression).

    • Superior vena cava compression produces jugular venous distention (JVD) and edema of the face and upper extremities.

    • Abdominal Aortic Aneurysm (AAA):

    • Frequently asymptomatic and discovered during routine physical exams or unrelated imaging.

    • Pulsatile mass located in the periumbilical region, palpable slightly to the left of the midline.

    • Presence of an audible systolic abdominal bruit over the mass.

    • Chronic lower back pain, dull epigastric discomfort, altered bowel elimination, and intermittent claudication.

  • Aneurysm rupture (critical emergency):

    • The most lethal complication of an aortic aneurysm; occurrence is significantly more likely in individuals who use tobacco.

    • Physical hallmark: Grey Turner sign, characterized by extensive ecchymosis and bruising over the bilateral flanks from retroperitoneal hemorrhage.

    • Leads to hypovolemic shock, profound hypotension, tachycardia, and death.

    • Emergency management: Rapid transport to the operating room with initiation of massive blood product transfusion protocols.

Surgical Repair and Postoperative Nursing Care for Aortic Aneurysms

  • Diagnostic evaluation of aortic aneurysms:

    • Chest and abdominal X-rays.

    • 12-lead ECG to rule out concomitant acute myocardial infarction.

    • Echocardiography.

    • Contrast-enhanced Computed Tomography (CT) scan and Magnetic Resonance Imaging (MRI) (CT scan is the gold standard for defining anatomical dimensions, vessel tortuosity, and branch vessel involvement).

  • Thresholds for interprofessional intervention:

    • Aneurysms <5.4 cm<5.4\,\text{cm} in diameter:

    • Managed with conservative therapy and medical surveillance.

    • Aggressive risk factor modification: Strict blood pressure normalization, tobacco cessation, and management of comorbid conditions.

    • Serial imaging surveillance: Ultrasound or CT scanning every 6–12 months6\text{--}12\text{ months}.

    • Aneurysms ≥5.5 cm\ge 5.5\,\text{cm} in diameter:

    • Surgical repair is strongly recommended due to high risk of spontaneous rupture.

  • Surgical repair modalities and complications:

    • Open Aneurysm Repair (OAR):

    • Open surgical incision requiring cross-clamping of the aorta above and below the aneurysm, incising the sac, and suturing a synthetic vascular graft.

    • Endovascular Aneurysm Repair (EVAR):

    • Minimally invasive procedure involving placement of a sutureless polyester or Dacron stent graft via the femoral artery under fluoroscopic guidance.

    • Endoleak:

    • The most common complication following EVAR.

    • Characterized by persistent blood flow leaking around the stent-graft seal into the old aneurysm sac.

    • Intra-abdominal hypertension (IAH) and Abdominal Compartment Syndrome:

    • A lethal complication following open or endovascular repair.

    • Markedly elevated intra-abdominal pressure compromises end-organ perfusion, necessitating emergency surgical abdominal decompression.

  • Preoperative and postoperative nursing management:

    • Preoperative nursing priorities:

    • Continuous assessment for clinical signs of impending or acute rupture (sudden hypotension, severe new-onset pain).

    • Baseline assessment of peripheral pulses across all extremities.

    • Baseline renal function (serum creatinine, blood urea nitrogen [BUN], hourly urine output) and neurological status.

    • Preoperative health teaching, risk factor reduction (tobacco cessation), and emotional support.

    • Postoperative ICU monitoring (24–48 hours24\text{--}48\text{ hours}):

    • Maintenance of graft patency: Monitor systemic blood pressure closely. Prolonged severe hypotension can lead to graft thrombosis, while severe hypertension can stress graft suture lines and induce bleeding.

    • Continuous cardiovascular monitoring: Rhythm telemetry for dysrhythmias and ischemic changes.

    • Infection control: Strict aseptic surgical dressing changes, monitoring body temperature, and administration of prophylactic IV antibiotics.

    • Gastrointestinal assessment: Auscultate bowel sounds, assess for the development of paralytic ileus, and monitor for signs of bowel ischemia (rectal bleeding, severe pain).

    • Neurological monitoring: Assess level of consciousness, pupil reactivity, and motor/sensory function in all extremities.

    • Peripheral perfusion: Serial palpation and grading of peripheral pulses (femoral, popliteal, posterior tibial, and dorsalis pedis), capillary refill time, skin color, and skin warmth.

    • Renal perfusion monitoring: Maintain hourly urine output measurements (target ≥30 mL/hr\ge 30\,\text{mL/hr}) and monitor daily serum creatinine and BUN levels, especially when aortic cross-clamping occurs above the renal arteries.

  • Ambulatory discharge education:

    • Instruct the patient to gradually increase activity levels over time.

    • Strictly avoid heavy lifting for a minimum of 6 weeks6\text{ weeks} following surgical intervention.

    • Teach the patient and family to inspect extremities daily for alterations in skin color, mottling, or temperature changes.

    • Instruct the patient on palpating peripheral pulses to recognize changes in pulse quality.

    • Report signs of surgical site infection or systemic compromise immediately: Incisional redness, swelling, increased pain, wound drainage, or a body temperature greater than 100 ∘F100\,^\circ\text{F}.